Dr. Giordano’s interview with eHealth Radio Network
December 15, 2020
Our CSO, Dr. Giordano, sat down with @EricDye to discuss JanOne, treating the #opioid industry, bringing to market drugs with non-addictive pain-relieving properties, and more. $JAN #Healthcare #Medical Listen to the full interview here via @eHealthRadio https://ehealthradio.podbean.com/e/janone-treating-the-opioid-industry-and-bringing-to-market-drugs-with-non-addictive-pain-relieving-properties READ MORE
September 24, 2020
Company continues to make progress on its potential treatment for PAD, a disease affecting 200 million people worldwide LAS VEGAS, NV Sept. 24, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that the Company has started production... READ MORE
September 22, 2020
Company pursuing additional application for JAN101 to treat COVID-19 complications Stable formulation and engineering for JAN101 will support Phase 2b PAD Study under the FDA’s Investigational New Drug (IND) #111703, expected to begin the first quarter of 2021 Scientific Advisory Board bolstered by expert additions LAS VEGAS, NV Sept. 23, 2020 – JanOne Inc. (Nasdaq:... READ MORE
JanOne Announces Strategic Plan to Divest its Legacy Businesses
September 16, 2020
Update on plans for sale of recycling business. Divesting will allow for focus on core life science assets LAS VEGAS, NV, Sept. 16, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, provided an update today regarding its initiatives to... READ MORE
September 3, 2020
Bottling and labeling partner Eurofins CDMO (Alphora Research, Inc.) to ensure JanOne clinical research maintains compliance with GMP and FDA regulations LAS VEGAS, NV Sept. 3, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has confirmed stability of its... READ MORE
August 28, 2020
Partnership to ensure clinical compliance for active and placebo dosing for PAD phase 2b trials planned for early 2021 and potential trials for treating Covid-19 vascular complications LAS VEGAS, NV Aug. 28, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving... READ MORE
August 26, 2020
Engineering batch for JAN101 complete and expectations are for GMP batch production to begin within 30 days LAS VEGAS, NV Aug. 26, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has successfully completed its initial engineering batch of JAN101.... READ MORE
August 21, 2020
-Introduction to JanOne scientific team -Strategy for upcoming planned Phase 2b trial of JAN101 -Business development updates, including planned COVID-19 treatment study and focus on commercialization and production capabilities LAS VEGAS, Aug. 21, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive,... READ MORE
JanOne to Present at The LD 500 Virtual Conference
August 19, 2020
Presentation to include recent and upcoming developments and overview of drug candidate JAN101 for the potential treatment of peripheral artery disease (PAD) as well as potential applications for COVID-19 vascular complications and planned IND submission process with FDA. Las Vegas, Aug. 19, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments to... READ MORE